Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report.

Pirozzi A, Cartenì G, Scagliarini S, Fusco M, Riccardi F.

Medicine (Baltimore). 2019 Mar;98(11):e14805. doi: 10.1097/MD.0000000000014805.

2.

Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report.

Popivanov GI, Bochev P, Hristoskova R, Mutafchiyski VM, Tabakov M, Philipov A, Cirocchi R.

Medicine (Baltimore). 2018 Feb;97(6):e9831. doi: 10.1097/MD.0000000000009831.

3.

Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.

Hanna F, Prakash A, Allan E, Khalafallah AA.

BMJ Case Rep. 2018 Mar 16;2018. pii: bcr-2017-223637. doi: 10.1136/bcr-2017-223637.

PMID:
29549134
4.

False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.

Inoue Y, Tamaki H, Yamagami T, Iwasaki H, Nakatsuka S, Soma T.

Eur J Haematol. 2007 Jul;79(1):88-90. Epub 2007 May 28. No abstract available.

PMID:
17532762
5.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
6.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
7.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
8.

[Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].

Oriuchi N, Higuchi T, Endo K, Tsukamoto N, Matsuda H, Kuji I, Murakami K, Nakajima K.

Kaku Igaku. 2009 Jun;46(2):96-9. Japanese.

PMID:
19637820
9.

[Therapeutic management of central nervous system lymphomas in a single hematological institute].

Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.

Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Hungarian.

PMID:
19812012
10.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
11.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.

PMID:
28236583
12.

Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report.

Gutsch J, Werthmann PG, Rosenwald A, Kienle GS.

Anticancer Res. 2018 Sep;38(9):5363-5369. doi: 10.21873/anticanres.12865.

PMID:
30194190
13.

A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.

Komoto D, Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Toyama Y, Satoh K, Ohno M, Kanenishi K, Ohkawa M.

Ann Nucl Med. 2006 Feb;20(2):157-60.

PMID:
16615426
14.

Treatment of prognosis of primary breast lymphoma: a review of 13 cases.

Lyons JA, Myles J, Pohlman B, Macklis RM, Crowe J, Crownover RL.

Am J Clin Oncol. 2000 Aug;23(4):334-6.

PMID:
10955857
15.

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, Derenzini E, Quirini F, Baccarani M.

Cancer. 2011 Mar 1;117(5):1010-8. doi: 10.1002/cncr.25579. Epub 2010 Oct 19.

16.

Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.

Jurczak W, Bryk AH, Mensah P, Gałązka K, Trofimiuk-Müldner M, Wyrobek Ł, Sawiec A, Skotnicki AB.

J Med Case Rep. 2016 May 14;10(1):123. doi: 10.1186/s13256-016-0875-x.

17.

Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.

Oh KC, Zang DY.

Korean J Intern Med. 2003 Mar;18(1):40-4.

18.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.

J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.

PMID:
26150440
19.

[Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].

Banzo J, Ubieto MA, Giraldo P, Razola P, Prats E, Tardin L, Santapau A, Parra A, Rambalde EF, Velilla J.

Rev Esp Med Nucl Imagen Mol. 2012 Mar-Apr;31(2):89-92. doi: 10.1016/j.remn.2011.03.018. Epub 2011 May 26. Spanish.

20.

Bilateral primary renal lymphoma in a pediatric patient: staging and response evaluation with ¹⁸F-FDG PET/CT.

Dhull VS, Mukherjee A, Karunanithi S, Durgapal P, Bal C, Kumar R.

Rev Esp Med Nucl Imagen Mol. 2015 Jan-Feb;34(1):49-52. doi: 10.1016/j.remn.2014.05.004. Epub 2014 Jul 21. Review.

Supplemental Content

Support Center